Technology
sector. At the end of 2023, the company announced plans to submit the OTTAVA robotic surgical system for an investigational device exemption (IDE) application to the FDA in the second half of 2024 to initiate clinical trials. OTTAVA is designed to create space in the
operating room (OR) – it incorporates four robotic arms into a standard size surgical table, with the robotic arms available when needed or stowed under the surgical table when not. The design removes barriers to movement and collaboration in robotic operating rooms and offers surgical teams the freedom and flexibility to adapt to clinical workflows and individualised patient needs. The system’s “twin motion” feature – unified
movement of the table and the robotic arms – is designed to allow surgical teams to address important clinical needs during surgery, such as the ability to reposition a patient without interrupting the procedure. Dr. Eduardo Parra-Davila, a Colorectal and
General Surgeon at the Palm Beach Digital Institute, comments: “The industry needs a system that is adaptable, easy to use in any OR in the world, and maintains space in the OR. As surgeons, we need space to improve the workflow in the OR, increase safety, and enable 360-degree patient access so we can perform at the capacity that we would like to. That’s where OTTAVA comes in. OTTAVA offers a design that incorporates into any OR and allows surgeons to do what they would like to do and know how to do, which is focus on the patient.” OTTAVA will join Johnson & Johnson MedTech’s portfolio of commercially available robotic systems, including the MONARCH Platform and the VELYS Robotic-Assisted Solution. The MONARCH Platform, used with the MONARCH Bronchoscope, is intended to provide bronchoscopic visualisation of and access to adult patient airways for diagnostic and
therapeutic procedures. The device enables physicians to use minimally invasive, robotic- assisted technology for peripheral lung procedures. The ability to reach small, hard- to-reach peripheral lung nodules at an earlier stage and with greater precision is helping to transform the future of interventional care for patients because nodules from lung cancer are typically small, deep in the lungs and difficult to reach, making early-stage diagnosis and treatment difficult. Lung cancer is the leading cause of cancer deaths worldwide, and early detection has been shown to increase survival rates if the disease is caught at a stage when it is more likely to be treated successfully VELYS is a solution for robotic-assisted Total
Knee Arthroplasty (TKA). Not only does the system help relieve the physical and mental toll of performing orthopaedic surgery, but it also improves patient outcomes and is associated with reduced resource utilisation compared to manual TKA. The technology behind the VELYS Robotic
Assisted Solution provides precision and accuracy, allowing surgeons to personalise TKA to a patient’s individual needs. DePuy Synthes UK’s General Manager, Gavin Meadows, commented: “Feedback from surgeons so far is that it is very simple to use and operate, allowing greater efficiency compared to some other operating systems; it has a smaller footprint; it is easier to move around; and it is easier to decontaminate.”
He explained that the VELYS robotic assisted solution is designed to facilitate procedural efficiency, predictability, and standardisation. It features a clear user interface, streamlined clinical application, adaptable workflow, and a fast registration process which helps improve procedural efficiency. This is achieved with limited disruption in the operating room, as the robot does not require a product
INNOVATIVE MULTI-TEST
POINT OF CARE SOLUTIONS
SKYLA® Clinical Chemistry
Analyser
Simple and user-friendly operation Simultaneously measures up to 15 marker parameters in a single reagent disc in 15 minutes
200µL (0.2cc) sample size of serum or lithium-heparinized whole blood or plasma samples
Excellent connectivity - interfaces with Conworx™, AegisPOC™ and Aqure™
AFIAS 1® A fast, simple and
reliable means of
detecting and
monitoring disease
Automated desktop analyser Over 40 markers - cardiac, cancer, diabetes, hormone and infection LIS/HIS connectivity All-in-one cartridge
10 μL, 30 μL, 50 μL finger-prick blood samples
ProciseDx® Accurate point of care
testing for IBD patients
Four assays: IFX - ADL - FCP - CRP Easy, immediate & accurate TDM from a finger prick sample
Quantitative results in just 2 to 5 mins 02476 377210
info@
bhr.co.uk
www.bhr.co.uk
Surgeon at Da Vinci console October 2024 I
www.clinicalservicesjournal.com 27
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
